As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.
10 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
10 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
Mar '25 |
+/-
%
|
||
Revenue | 1.20 1.20 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -50 -50 |
20%
20%
|
EBIT (Operating Income) EBIT | -51 -51 |
19%
19%
|
Net Profit | -30 -30 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.
Head office | United States |
CEO | Talat Imran |
Employees | 140 |
Founded | 2012 |
Website | www.ranitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.